Wellington Management Group LLP lowered its stake in Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) by 77.1% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 2,506,138 shares of the life sciences company's stock after selling 8,417,221 shares during the quarter. Wellington Management Group LLP owned 3.25% of Integra LifeSciences worth $56,839,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Quadrant Capital Group LLC boosted its position in shares of Integra LifeSciences by 5,960.9% during the fourth quarter. Quadrant Capital Group LLC now owns 1,394 shares of the life sciences company's stock valued at $32,000 after buying an additional 1,371 shares during the last quarter. Sterling Capital Management LLC lifted its holdings in Integra LifeSciences by 821.7% in the fourth quarter. Sterling Capital Management LLC now owns 2,166 shares of the life sciences company's stock valued at $49,000 after acquiring an additional 1,931 shares during the period. Nisa Investment Advisors LLC lifted its holdings in Integra LifeSciences by 599.6% in the fourth quarter. Nisa Investment Advisors LLC now owns 3,267 shares of the life sciences company's stock valued at $74,000 after acquiring an additional 2,800 shares during the period. Covestor Ltd raised its stake in shares of Integra LifeSciences by 61.8% in the fourth quarter. Covestor Ltd now owns 5,423 shares of the life sciences company's stock worth $123,000 after buying an additional 2,071 shares during the period. Finally, Empowered Funds LLC purchased a new stake in shares of Integra LifeSciences during the fourth quarter worth about $180,000. Institutional investors own 84.78% of the company's stock.
Integra LifeSciences Price Performance
NASDAQ IART traded up $0.45 during trading hours on Tuesday, reaching $12.77. The company's stock had a trading volume of 148,945 shares, compared to its average volume of 1,038,670. The firm has a market capitalization of $992.38 million, a price-to-earnings ratio of -141.87, a P/E/G ratio of 0.73 and a beta of 1.27. Integra LifeSciences Holdings Co. has a 1-year low of $11.60 and a 1-year high of $32.66. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.20 and a quick ratio of 0.73. The company's 50-day moving average is $15.85 and its two-hundred day moving average is $20.83.
Integra LifeSciences (NASDAQ:IART - Get Free Report) last announced its earnings results on Monday, May 5th. The life sciences company reported $0.41 EPS for the quarter, missing analysts' consensus estimates of $0.43 by ($0.02). Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The firm had revenue of $382.65 million for the quarter, compared to analyst estimates of $381.17 million. During the same period in the previous year, the company earned $0.55 EPS. Integra LifeSciences's revenue was up 3.7% compared to the same quarter last year. On average, equities analysts predict that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current year.
Wall Street Analysts Forecast Growth
A number of brokerages recently issued reports on IART. Truist Financial decreased their price target on Integra LifeSciences from $26.00 to $19.00 and set a "hold" rating for the company in a research note on Friday, April 11th. JMP Securities decreased their target price on Integra LifeSciences from $35.00 to $25.00 and set a "market outperform" rating for the company in a research report on Friday, May 9th. Wells Fargo & Company decreased their target price on Integra LifeSciences from $25.00 to $13.00 and set an "equal weight" rating for the company in a research report on Tuesday, May 6th. JPMorgan Chase & Co. decreased their target price on Integra LifeSciences from $24.00 to $12.00 and set an "underweight" rating for the company in a research report on Tuesday, May 6th. Finally, Argus raised Integra LifeSciences from a "hold" rating to a "buy" rating in a research report on Monday, March 31st. Four investment analysts have rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, Integra LifeSciences currently has a consensus rating of "Hold" and an average target price of $18.63.
Check Out Our Latest Analysis on Integra LifeSciences
About Integra LifeSciences
(
Free Report)
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.
Further Reading
Before you consider Integra LifeSciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Integra LifeSciences wasn't on the list.
While Integra LifeSciences currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
